Pharmaceutical industry in India

DGAP-News: SHS invests in Swiss-German specialty drug company Develco Pharma

Retrieved on: 
Thursday, December 17, 2020
Life sciences, Health sciences, Health care, Biopharmaceuticals, Biotechnology, Pharmaceutical industry, Specialty drugs in the United States, Pharmaceutical industry in India, Pharmaceutical industry in China, SHS Gesellschaft für Beteiligungsmanagement mbH, Develco Pharma

Develco specializes in the development, approval and production of innovative and generic specialty drugs and offers a unique and broad set of formulation technologies for orally administered medicines with specific substance-release profiles

Key Points: 
  • Develco specializes in the development, approval and production of innovative and generic specialty drugs and offers a unique and broad set of formulation technologies for orally administered medicines with specific substance-release profiles
    Tbingen-based SHS Gesellschaft fr Beteiligungsmanagement mbH is investing from its SHS V fund in the Swiss-German specialty drug company Develco Pharma.
  • Develco has state-of-the-art production operations of its own; its customers include world-leading pharmaceuticals companies that market the products internationally.
  • Develco Pharma has earned an excellent reputation as a developer and producer in this field over the past 14 years.
  • The SHS fund's European based investors include pension funds, strategic investors, funds of funds, family offices, entrepreneurs and the SHS management team.

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

Retrieved on: 
Tuesday, December 15, 2020
Health, Manufacturing, Clinical trials, Other Manufacturing, Pharmaceutical, Biotechnology, Health care, Health, Immunosuppressants, Peptides, Voclosporin, Pharmaceutical industry in China, Lonza, Aurinia, Visp, Pharmaceutical industry in India

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia) and Lonza Ltd. (SIX: LONN) ("Lonza") today announced they have expanded their exclusive manufacturing relationship.

Key Points: 
  • Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia) and Lonza Ltd. (SIX: LONN) ("Lonza") today announced they have expanded their exclusive manufacturing relationship.
  • The parties entered into a collaborative agreement to build a dedicated manufacturing capacity within Lonzas existing small molecule API facility in Visp, Switzerland.
  • The agreement, which is conditional upon U.S. regulatory approval of voclosporin, does not impact the launch supply for voclosporin as this is secured by existing inventory.
  • A dedicated production capability will help keep our manufacturing costs down and ensure long-term flexibility to meet future demand for years to come.

Overland Pharmaceuticals Debuts as Premier Biopharmaceutical Company to Bring Innovative Medicines to Asia and Worldwide

Retrieved on: 
Wednesday, December 9, 2020
Biotechnology, Pharmaceutical, Health, Hillhouse Capital Group, Hillhouse, Overland, Pharmaceutical industry in China, Health, Pharmaceutical industry in India, Investment, Overland Pharmaceuticals, Hillhouse Capital

Backed by Hillhouse Capital (Hillhouse), Overland Pharmaceuticals (Overland) today announced its official launch with a mission to bring innovative medicines to underserved patients in Asia and around the world.

Key Points: 
  • Backed by Hillhouse Capital (Hillhouse), Overland Pharmaceuticals (Overland) today announced its official launch with a mission to bring innovative medicines to underserved patients in Asia and around the world.
  • The global investment firm Hillhouse is providing Overland with support to build a fully integrated biopharmaceutical company through collaborations in select disease areas.
  • The company will operate in three international offices in Shanghai and Beijing, China and Boston, Massachusetts.
  • Overland Pharmaceuticals is building a fully integrated biopharma company with a mission to bring innovative medicines to underserved patients in Asia and around the world.

Global Nasal delivery devices Markets, 2019-2020 & 2027: Rising Adoption of Self-Administration Practices & Consolidation of Nasal Delivery Device Industry

Retrieved on: 
Monday, December 7, 2020
Health sciences, Health care, Health, Dosage forms, Asthma, Respiratory therapy, Inhaler, Puffer, Dr. Reddy's Laboratories, Novartis, Pharmaceutical industry in India, Medication

The market is estimated to grow with a CAGR of 6.4% from 2020 to 2027.

Key Points: 
  • The market is estimated to grow with a CAGR of 6.4% from 2020 to 2027.
  • An inhaler (also known as a pump, puffer, or allergy spray) is a nasal delivery device used for delivering medicines into the lungs via person's breathing mechanism.
  • This device helps deliver medical treatment to the targeted region of the body, thereby reducing the side effects of oral medications.
  • ; Cadila Pharmaceuticals Ltd.; Novartis AG; Dr. Reddy's Laboratories; and Neurelis, Inc. are among the leading companies operating in the nasal delivery devices market.

Contract Research Organizations (CROs) Market to Reach $64.4 Billion by 2027, Growing at a CAGR of 6.5% From 2020 With COVID-19 Impact- Meticulous Research® Analysis

Retrieved on: 
Friday, December 4, 2020
Life sciences, Biotechnology, Articles, Health sciences, Pharmaceutical industry, Pharmaceuticals policy, Biosimilar, Drugs, Contract research organization, Biopharmaceutical, Pharmaceutical industry in India, Bioprocess

The growth of the contract research organizations market is mainly attributed to the rising demand for biopharmaceuticals, increasing number of clinical trials, and growing government support for biopharmaceutical manufacturing.

Key Points: 
  • The growth of the contract research organizations market is mainly attributed to the rising demand for biopharmaceuticals, increasing number of clinical trials, and growing government support for biopharmaceutical manufacturing.
  • Also, significant opportunities from emerging markets, increasing demand for biosimilars, and continuous advancements in bioprocessing techniques offer growth opportunities for the players operating in the contract research organizations market.
  • In terms of service, the clinical research services segment is estimated to account for the largest share of the overall CROs market in 2020.
  • Based on therapeutic area, the oncology segment is estimated to account for the largest share of the overall contract research organizations market in 2020.

Contract Research Organizations (CROs) Market to Reach $64.4 Billion by 2027, Growing at a CAGR of 6.5% From 2020 With COVID-19 Impact- Meticulous Research® Analysis

Retrieved on: 
Friday, December 4, 2020
Life sciences, Biotechnology, Articles, Health sciences, Pharmaceutical industry, Pharmaceuticals policy, Biosimilar, Drugs, Contract research organization, Biopharmaceutical, Pharmaceutical industry in India, Bioprocess

The growth of the contract research organizations market is mainly attributed to the rising demand for biopharmaceuticals, increasing number of clinical trials, and growing government support for biopharmaceutical manufacturing.

Key Points: 
  • The growth of the contract research organizations market is mainly attributed to the rising demand for biopharmaceuticals, increasing number of clinical trials, and growing government support for biopharmaceutical manufacturing.
  • Also, significant opportunities from emerging markets, increasing demand for biosimilars, and continuous advancements in bioprocessing techniques offer growth opportunities for the players operating in the contract research organizations market.
  • In terms of service, the clinical research services segment is estimated to account for the largest share of the overall CROs market in 2020.
  • Based on therapeutic area, the oncology segment is estimated to account for the largest share of the overall contract research organizations market in 2020.

Amring Pharmaceuticals Inc. Acquires LYSTEDA®

Retrieved on: 
Wednesday, December 2, 2020
Biotechnology, General Health, Pharmaceutical, Health, Pharmaceuticals policy, Health care, Health, Pharmaceutical industry, Pharmaceutical industry in China, Pharmacy in China, Science and technology in the People's Republic of China, Generic drug, Authorized generics, Pharmaceutical industry in India, Amring Pharmaceuticals Inc., Ferring International Center S.A.

Amring has been marketing the authorized generic version of LYSTEDA in the USA since March 14, 2016.

Key Points: 
  • Amring has been marketing the authorized generic version of LYSTEDA in the USA since March 14, 2016.
  • With the acquisition of LYSTEDA, Amring is further securing its position as a market leader in the treatment of HMB and expands product opportunities in markets outside of the USA, stated Daniel Carbery, President and CEO of Amring.
  • Amring Pharmaceuticals is a privately held pharmaceutical company that provides value brands and niche generics to the market.
  • Amring is uniquely positioned to leverage its partners expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.

Arrakis Therapeutics Appoints Patrizio Renzetti as Vice President of Human Resources

Retrieved on: 
Thursday, November 19, 2020
Research, Other Health, General Health, Professional services, Pharmaceutical, Oncology, Genetics, Science, Other Professional Services, Biotechnology, Human resources, Health, Other Science, Life sciences, Biotechnology, Health sciences, Arrakis Therapeutics, Canopus in fiction, Arrakis, Agios Pharmaceuticals, Biopharmaceutical, Pharmaceutical industry in India

Arrakis Therapeutics , a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that Patrizio Renzetti has joined the company as Vice President, Human Resources.

Key Points: 
  • Arrakis Therapeutics , a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that Patrizio Renzetti has joined the company as Vice President, Human Resources.
  • Patrizio is an experienced human resources leader with broad expertise at dynamic high-growth companies, both large and small, including Agios Pharmaceuticals, Lilly, and Procter & Gamble.
  • View the full release here: https://www.businesswire.com/news/home/20201119005323/en/
    Arrakis Vice President of HR Patrizio Renzetti (Photo: Business Wire)
    Patrizio is an ideal fit to lead the HR function at Arrakis, having built high-performing R&D organizations at fully integrated, global companies, said Michael Gilman, Chief Executive Officer of Arrakis.
  • He joins Arrakis from Agios Pharmaceuticals where he most recently served as Vice President of Human Resources for R&D, Technical Operations, and Europe, and previously led the Talent Acquisition group.

GENFIT: Third Quarter 2020 Financial Information and Launch of Renegotiation of Convertible Bond

Retrieved on: 
Monday, November 16, 2020
Burlington, North Carolina, LabCorp, Pharmaceutical industry in India, Life sciences, Health, Articles

As of September 30, 2020, the Companys cash and cash equivalents amounted to 199.3 million compared with 303.0 million one year earlier.

Key Points: 
  • As of September 30, 2020, the Companys cash and cash equivalents amounted to 199.3 million compared with 303.0 million one year earlier.
  • Revenues for the first nine months of 2020 amounted to 350 thousand compared to 31 million for the same period in 2019.
  • Revenues for the 3rd quarter resulted mainly from services provided and revenues under the licensing and collaboration agreements signed with Labcorp and Terns Pharmaceuticals.
  • 4 At this stage, the renegotiation of the 2022 OCEANE terms remains in draft form.

Mint Pharmaceuticals' CEO Jaiveer Singh Named One of Canada's Top 40 Under 40® for 2020

Retrieved on: 
Thursday, October 29, 2020
Pharmaceuticals policy, Health, Canadian Imperial Bank of Commerce, S&P/TSX 60 Index, Pharmaceutical industry in China, Pharmaceutical industry in India

Mint Pharmaceuticals Inc. ("Mint") is pleased to announce that Jaiveer Singh, Chief Executive Officer, has been named a Recipient of Canada's Top 40 Under 40 for 2020.

Key Points: 
  • Mint Pharmaceuticals Inc. ("Mint") is pleased to announce that Jaiveer Singh, Chief Executive Officer, has been named a Recipient of Canada's Top 40 Under 40 for 2020.
  • MISSISSAUGA, ON, Oct. 29, 2020 /PRNewswire/ - Canada's Top 40 Under 40 is an annual recognition of the exceptional achievements of 40 outstanding Canadians under the age of 40.
  • Canadian owned and operated, Mint Pharmaceuticals Inc. ("Mint") is a leading manufacturer of high quality and affordable generic pharmaceutical products.
  • In 2019 and 2020, the company was recognized by Deloitte and CIBC as one of Canada's Best Managed Businesses.